Yahoo
    Taiwan - Delayed Quote TWD

    PharmaEssentia Corporation (6446.TW)

    1,240.00 +15.00 (+1.22%)
    As of 9:20:33 AM GMT+8. Market Open.
    Loading Chart for 6446.TW
    Chart Range Bar
    Interval:
    In partnership with ChartIQ

    Recent News

    Ropeg Secures ET Approvals Across Asia and the U.S., Highlighting Treatment Access Gap in Europe

    Ropeg Secures ET Approvals Across Asia and the U.S., Highlighting Treatment Access Gap in Europe
    Business Wire 13h ago
    Ropeg Advances Essential Thrombocythemia Treatment Worldwide as European Patients Await Access

    Ropeg Advances Essential Thrombocythemia Treatment Worldwide as European Patients Await Access
    Business Wire 14h ago
    PharmaEssentia’s Ropeg Expands Global ET Approvals While Europe Awaits Regulatory Clearance

    PharmaEssentia’s Ropeg Expands Global ET Approvals While Europe Awaits Regulatory Clearance
    Business Wire 15h ago
    Ropeg Wins ET Approvals Across Major Markets as European Patients Await Expanded Access

    Ropeg Wins ET Approvals Across Major Markets as European Patients Await Expanded Access
    Business Wire 14h ago
    Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access

    Ropeg Gains ET Approvals in Major Global Markets as European Patients Await Access
    Business Wire 15h ago
    PharmaEssentia to Participate in Upcoming Jefferies and Citi Healthcare Conferences

    PharmaEssentia to Participate in Upcoming Jefferies and Citi Healthcare Conferences
    Business Wire 1d ago
    PharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid Tumors

    PharmaEssentia to Present Early-Stage Pipeline Data at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, Highlighting Immuno-Oncology Approaches for Solid Tumors
    Business Wire 8d ago
    PharmaEssentia to Present Data at 18th International Congress on Myeloproliferative Neoplasms Highlighting Unmet Need with Current Therapies and Real-World Use of BESREMi® in Essential Thrombocythemia and Polycythemia Vera

    PharmaEssentia to Present Data at 18th International Congress on Myeloproliferative Neoplasms Highlighting Unmet Need with Current Therapies and Real-World Use of BESREMi® in Essential Thrombocythemia and Polycythemia Vera
    Business Wire 15d ago
    From PV to ET to PMF, PharmaEssentia Has Come A Long Way in Fighting Diseases

    From PV to ET to PMF, PharmaEssentia Has Come A Long Way in Fighting Diseases
    Business Wire 18d ago
    From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments

    From Taiwan to the World: PharmaEssentia Expands Global Reach With New Drug Approvals, Overseas Investments
    Business Wire 18d ago
    From Taiwan to the World: PharmaEssentia Builds a Scientist-Led, Fully Integrated Global Biopharmaceutical Company with Patients at Its Core

    From Taiwan to the World: PharmaEssentia Builds a Scientist-Led, Fully Integrated Global Biopharmaceutical Company with Patients at Its Core
    Business Wire 18d ago

    Related Tickers

    Mobilize your Website
    View Site in Mobile | Classic
    Share by: